Physician profile
Zakeih Chaker
NPI 1720436082
$3,921.01
in general payments reported to CMS, 2019-2025
27 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $246 · 2021: $372 · 2022: $308 · 2023: $447 · 2024: $1,195 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,669 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,668.80 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $759.18 | 2019-2025 | Confirm Rx, Aveir, Assurity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $368.51 | 2021-2023 | Lifevest |
| Medtronic, INC. | $322.60 | 2024-2025 | Symplicity G3, Aurora Ev-Icd Mri Surescan |
| Novartis Pharmaceuticals Corporation | $251.07 | 2023-2025 | |
| Scpharmaceuticals INC. | $237.19 | 2023-2025 | |
| Pfizer INC. | $186.02 | 2024-2025 | |
| Boston Scientific Corporation | $180.33 | 2021-2025 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor, Varithena Administration Pack |
| E.R. Squibb & Sons, L.L.C. | $167.15 | 2023-2025 | Eliquis, Camzyos |
| Amgen INC. | $163.29 | 2021-2025 | Repatha, Repatha |
| Abiomed | $155.44 | 2021-2025 | Impella |
| Novo Nordisk INC | $155.18 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $154.84 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.39 | 2024-2025 | Jardiance |
| Medicomp INC | $125.85 | 2023-2024 | Telepatch Cardiac Monitor |
| Actelion Pharmaceuticals US, INC. | $104.01 | 2024 | Opsumit, Uptravi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $83.44 | 2023-2024 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $45.44 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $45.14 | 2025 | |
| Heartflow, INC. | $43.74 | 2023-2024 | Ffrct |
| Atricure, INC. | $37.06 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $36.91 | 2025 | Wainua |
| Nevro Corp. | $34.95 | 2024 | Senza |
| Chiesi USA, INC. | $26.98 | 2024 | Kengreal |
| Irhythm Technologies, INC. | $22.38 | 2023 | Zio Xt Patch |
| Integra Lifesciences Corporation | $20.60 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Esperion Therapeutics, INC. | $20.21 | 2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $20.11 | 2023 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zakeih Chaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.